Navigation Links
Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Date:10/1/2007

eatment of cancer and inflammatory diseases, scheduled to enter Phase 1 clinical trials in the second half of 2007, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 1 study of RDEA119 in patients with advanced cancer and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro ... Alliance (HITRUST) under its Common Security Framework (CSF). ... Security and Privacy Manager, "We appreciate this rigorous, ... of commitment that this certification signifies. Our business ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s internal ...
(Date:8/21/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), IBM (NYSE: IBM - Free ... Report ), GlaxoSmithKline plc (NYSE: GSK - Free Report ... Report ). Today, Zacks is promoting its ,Buy, ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3ScriptPro Achieves HITRUST Certification 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... , , , ... CYBX ) today announced that the U.S. Food and Drug Administration ("FDA") ... post-approval dosing study in depression patients treated with VNS Therapy(TM). , ... 2008 to reduce the number of study subjects from 460 to 330 ...
... , , , ... this month the University of Wisconsin Cancer Center Riverview became ... with a breakthrough treatment of skin cancer. Located within Riverview ... first to treat skin cancer patients with the FDA-cleared Axxent(R) ...
Cached Medicine Technology:Cyberonics Provides Update on Depression Post-Approval Study 2Cyberonics Provides Update on Depression Post-Approval Study 3First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Stevin McNamara’s original ... raga, the traditional form of music that has existed in ... raga is not only a scale or some fixed sequence ... correctly performed — at the appropriate time of day or ... spiritual connection between raga and musician occurs, in its turn ...
(Date:8/21/2014)... (HealthDay News) -- Black Americans are at greater risk ... the blood sugar disease, a new study says. ... Nutrition Examination Survey, which evaluates about 5,000 people each ... of a condition known as diabetic macular edema -- ... with diabetes. Diabetic macular edema occurs when fluid ...
(Date:8/21/2014)... American Associations for Dental Research (IADR/AADR) have published a ... Decades of Decline." This study, by lead researcher Gary ... follows edentulism (tooth loss) over the last hundred years ... requiring dentures. It is published in the OnlineFirst portion ... ( JDR ). , The researchers of this ...
(Date:8/21/2014)... Indianapolis, Indiana (PRWEB) August 21, 2014 ... independent employee benefits advisory organization, is pleased to ... Firm. Based in Knoxville, Tennessee, Trinity Benefit ... forged close, long-term relationships with their clients. Their ... strategic planning and objective setting, implementation, and monitoring. ...
(Date:8/21/2014)... According to a new market report ... (Enteral Feeding Tubes, Enteral Feeding Pumps, Administration Reservoir, Giving ... Share, Growth, Trends and Forecast,2013 - 2019" the global ... billion in 2012 and is estimated to reach a ... a CAGR of 6.2% from 2013 to 2019. , ...
Breaking Medicine News(10 mins):Health News:Raga Cycle of Shakti Guitar Follows The Sun 2Health News:Raga Cycle of Shakti Guitar Follows The Sun 3Health News:Blacks May Face Higher Risk of Diabetes-Linked Vision Loss 2Health News:Study shows steep decline in tooth loss, increase in socioeconomic disparities 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... Jan. 26 United American Healthcare,Corporation (Nasdaq: ... will release its financial results for the second fiscal,quarter ... after market,close. The Company will host a conference ... discuss the results. , Participation ...
... recommends that people consume at least 5 percent ... acids.-- It,s recommended that the omega-6 comes from ... fatty acids may lower the risk for heart ... resistance, reduce diabetes risk and lower blood pressure.DALLAS, ...
... during act reinforces maternal bond , , MONDAY, Jan. 26 ... to neglect their children, Australian researchers report. , In ... their children for 15 years and found that the ... risk of neglect. , Mothers who breast-fed for less ...
... be hidden in DNA , , MONDAY, Jan. 26 (HealthDay News) ... make you human are genes that may determine whether you ... two types of twins shows that genetics might affect social ... are closing in on some of those "personality" genes. , ...
... all breast cancers are the same, and not all will ... accurately determine which tumors will metastasize, many patients do not ... University has now refined breast cancer identification so that each ... treated. , The new approach based on a ...
... A new study finds swimming, having a private well ... consumption were major risk factors for bacterial intestinal infections ... food, such as the current Salmonella outbreak ... people in 43 states, account for only about 10 ...
Cached Medicine News:Health News:United American Healthcare Corporation to Host Fiscal 2009 Second Quarter Results Conference Call February 5th 2Health News:American Heart Association Science Advisory - Omega-6 Fatty Acids: Make Them a Part of Heart-Healthy Eating 2Health News:American Heart Association Science Advisory - Omega-6 Fatty Acids: Make Them a Part of Heart-Healthy Eating 3Health News:American Heart Association Science Advisory - Omega-6 Fatty Acids: Make Them a Part of Heart-Healthy Eating 4Health News:Moms Who Breast-Feed Less Likely to Neglect Child 2Health News:Popular or Not? Your Genes May Help Decide 2Health News:Popular or Not? Your Genes May Help Decide 3Health News:An individualized approach to breast cancer treatment 2Health News:Was it the chicken salad or the swim? 2Health News:Was it the chicken salad or the swim? 3
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 550 to 700....
Designed to remove cell debris or tissue remnants from the retina....
... Medtronic presents the Streamline family of ... have taken the gold standard in temporary ... that make them easy to use and ... Model 6491 Unipolar Pediatric Temporary Pacing Lead ...
Lytec Medical 2004 practice management software is designed to help you more effectively manage your accounts receivable as well as track authorizations and inventory. Lytec Medical XE provides outst...
Medicine Products: